Compare Eni SpA (E) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs BIO-TECHNE Corp — how do they compare? Eni SpA trades at $48.35 (market cap $70.34B), while BIO-TECHNE Corp trades at $71.74 (market cap $11.14B). The key difference: Eni SpA is far larger — about 6.3× BIO-TECHNE Corp's market cap, and Eni SpA pays the higher dividend (4.99%). Which is the better fit depends on your goals.
| E | TECH | |
|---|---|---|
Market Cap | $70.34B | $11.14B |
Sector | Energy | Health |
52-Week High | $57.61 | $71.48 |
52-Week Low | $32.93 | $43.31 |
Enterprise Value | $89.25B | $11.22B |
Dividend Yield | 4.99% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $49.55, up 0.22% with a bullish technical signal supported by moving averages. The company shows stable cash flow generation with $238M net cash flow in 2025 and maintains a dividend of $0.63. Recent strategic expansions into renewable fuels, lithium, and energy trading through partnerships with BMW, Mercuria, and UKAEA highlight diversification efforts. Valuation metrics appear reasonable with P/E of 21.6 and EV/EBITDA of 3.83, though revenue has declined from $132.5B in 2022 to $82.15B in 2025.
The outlook balances strategic growth initiatives against revenue pressures. Opportunities exist in energy transition projects and trading expansion, but risks include oil price volatility and execution challenges. Analyst sentiment is mixed with 34.6% buy ratings versus 61.5% hold, suggesting cautious optimism. The stock's investment case hinges on successful diversification while managing core energy market exposure.
Bio-Techne Corporation (TECH) trades at $71.66, near its all-time high, following Merck KGaA's announced $73 per share cash acquisition offer, representing a 24% premium. The stock shows a bullish technical trend, while fundamental metrics reveal a high valuation with a P/E of 102.12 and a net income margin of 9.05%. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. Analyst consensus is evenly split between Buy and Hold, with a $67.75 price target below the current offer price.
The investment outlook is dominated by the pending acquisition by Merck KGaA. The primary opportunity is the realization of the $73 per share offer, providing a clear exit near current levels. Key risks include potential deal completion delays, regulatory scrutiny, and shareholder litigation questioning the fairness of the price. Should the deal fall through, the stock faces significant downside pressure given its stretched valuation and recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
